University of Manchester’s UMI3 has joined Frontier IP and Ingenza as a shareholder in newly-founded Plymouth antibiotics spinout Amprologix.
University of Manchester’s commercialisation arm UMI3 has picked up a stake in UK-based Amprologix, a newly-founded antibiotics spinout from University of Plymouth.
Commercialisation firm Frontier IP will own 10% of the new company and synthetic biology provider Ingenza has also taken equity.
Amprologix has been formed to commercialise a class of antibiotics called epidermicin capable of killing infections resistant to drugs such as methicillin, an antibiotic first discovered in 1960.
A dearth of new antibiotics has led…
